Abstract
There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
Keywords: Single nucleotide polymorphism, SNP, variation, serotonin, human, Japanese, MAP, abuse, polymorphism, AP, nucleotide polymorphisms, polymorphic variants
Current Neuropharmacology
Title: Association Analysis of the Tryptophan Hydroxylase 2 Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis
Volume: 9 Issue: 1
Author(s): Hideaki Kobayashi, Hiroshi Ujike, Nakao Iwata, Toshiya Inada, Mitsuhiko Yamada, Yoshimoto Sekine, Naohisa Uchimura, Masaomi Iyo, Norio Ozaki, Masanari Itokawa and Ichiro Sora
Affiliation:
Keywords: Single nucleotide polymorphism, SNP, variation, serotonin, human, Japanese, MAP, abuse, polymorphism, AP, nucleotide polymorphisms, polymorphic variants
Abstract: There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
Export Options
About this article
Cite this article as:
Kobayashi Hideaki, Ujike Hiroshi, Iwata Nakao, Inada Toshiya, Yamada Mitsuhiko, Sekine Yoshimoto, Uchimura Naohisa, Iyo Masaomi, Ozaki Norio, Itokawa Masanari and Sora Ichiro, Association Analysis of the Tryptophan Hydroxylase 2 Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017335
DOI https://dx.doi.org/10.2174/157015911795017335 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy
and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Exploring the Relationship of Functional Network Connectivity to Latent Trajectories of Alcohol Use and Risky Sex
Current HIV Research Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation
CNS & Neurological Disorders - Drug Targets Editorial:
Neuroscience and Biomedical Engineering (Discontinued) Scopolamine and Depression: A Role for Muscarinic Antagonism?
CNS & Neurological Disorders - Drug Targets Role of LXR and ABCA1 in the Pathogenesis of Alzheimers Disease -Implications for a New Therapeutic Approach
Current Alzheimer Research Gq protein-Coupled Receptors as Targets for Anesthetics
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Alzheimer Research Cannabis: A Neurological Remedy or a Drug of Abuse in India
CNS & Neurological Disorders - Drug Targets Reactive Astrocytes as Potential Manipulation Targets in Novel Cell Replacement Therapy of Parkinsons Disease
Current Drug Targets Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Epigenetics and Periodontal Disease: Hope to Tame the Untameable
Current Gene Therapy Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions
Current Alzheimer Research Development and Validation of a Fluorescence-Based HTS Assay for the Identification of P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Application in Electrochemistry of Graphene-Modified Electrodes
Micro and Nanosystems Acknowledgements to Reviewers:
Recent Patents on CNS Drug Discovery (Discontinued) RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets